Skip to main content
  • COVID-19
    • COVID-19 vaccines and cancer
      • FAQs
      • FAQs in-language
      • SerOzNET Study
    • COVID-19 information for people affected by cancer
      • Managing your cancer care in the context of COVID-19
      • Looking after your mental wellbeing
      • Canada
      • Ireland
      • UK
      • USA
    • COVID-19 information for children and young people with cancer
    • Cancer Won’t Wait
    • Cancer and COVID-19 - what it means for our Mob
      • COVID-19 vaccines: Information for Aboriginal and Torres Strait Islander people affected by cancer
      • Act early for our Mob's health
    • Guidance for health professionals
      • Diagnosis
      • Treatment
      • Surgery
      • Medical oncology
      • Radiation oncology
      • Primary care
      • Telehealth
      • Clinical trials
      • Follow-up care
      • Supportive and Palliative care
      • Cancer care for cancer patients with COVID-19
      • COVID-19 vaccines and cancer
      • Recovery
    • Research articles
      • Review articles
      • Data articles
      • Recommendations articles
      • Shared experience articles
      • COVID-19 vaccines and cancer articles
    • Cancer care in the time of COVID-19: A conceptual framework
    • Optimal cancer care during the COVID-19 pandemic: the Principles
    • The impact of COVID-19 on cancer services
    • COVID-19 Recovery: Implications for cancer care
      • Expanded use of telehealth
      • Changes to prevention and early detection
      • Virtual multidisciplinary team meetings
      • Modifications to treatment schedules
      • Hypofractionated radiotherapy
      • Oncology hospital in the home
      • Responsive patient support
      • Innovative care and hospital infrastructure models
      • Shared follow-up and survivorship care
      • Supportive and palliative care
      • Cancer research and clinical trials
      • Collaboration in the oncology sector and data sharing
      • Acknowledgements
  • About us
    • Organisational structure
    • Accountability and reporting
      • Annual reports
    • Who we work with
      • Roles & functions
      • Advisory Council
      • Advisory groups
      • Consumer engagement
      • Government cancer control organisations
    • Information publication scheme
      • Information publication scheme plan
      • Freedom of information act
        • The FOI request process
      • FOI disclosure log
    • Reconciliation action plan
    • Employment opportunities
  • News and media
    • News
    • Subscribe to our eNewsletter
  • Contact us
Cancer Australia
Choose Language
  • العربية
  • 简体中文
  • 繁體中文
  • Ελληνικά
  • हिन्दी
  • Italiano
  • 한국어
  • Español
  • Tagalog
  • Tiếng Việt
  • العربية
  • 简体中文
  • 繁體中文
  • Ελληνικά
  • हिन्दी
  • Italiano
  • 한국어
  • Español
  • Tagalog
  • Tiếng Việt
  • العربية
  • 简体中文
  • 繁體中文
  • Ελληνικά
  • हिन्दी
  • Italiano
  • 한국어
  • Español
  • Tagalog
  • Tiếng Việt
  • Home
  • Cancer types
  • Impacted by Cancer
  • Awareness
  • Research
  • Resources
  • Clinicians hub
  • Key initiatives
  • Home
  • Cancer types
    • Bladder cancer
    • Bowel cancer
    • Brain cancer
    • Breast cancer
    • Breast cancer in men
    • Breast cancer in young women
    • Cervical cancer
    • Children’s cancer
    • Endometrial cancer
    • Fallopian cancer
    • Gestational trophoblastic disease
    • Gynaecological cancers
    • Head and neck cancer
    • Kidney cancer
    • Leukaemia
    • Liver cancer
    • Lung cancer
    • Lymphoma
    • Melanoma
    • Mesothelioma cancer
    • Myeloma
    • Neuroendocrine tumours
    • Oesophageal cancer
    • Ovarian cancer
    • Pancreatic cancer
    • Prostate cancer
    • Sarcoma
    • Stomach cancer
    • Testicular cancer
    • Thyroid cancer
    • Unknown primary cancer
    • Uterine sarcoma
    • Vaginal cancer
    • Vulvar cancer
  • Impacted by Cancer
    • What is cancer
    • Physical changes
    • Treatment
    • Keeping healthy
    • Emotions
    • Family and relationships
    • Living with cancer
  • Awareness
    • Your cancer risk
    • Screening
    • Interactive body map
  • Research
    • Cancer Research in Australia
    • Data and statistics
    • Australian Clinical Trials
    • Support for cancer clinical trials
    • Grants and funding
  • Resources
    • Cancer Australia Publications
    • Clinical Practice Guidelines
    • Position statements
    • Resources in other languages
    • Cancer Australia websites
    • Cancer risk online assessment tools
    • Other tools and resources
    • Podcasts
    • Cancer support organisations
    • Glossary
  • Clinicians hub
    • GP guides and resources
    • Guidelines by cancer type
    • Optimal cancer care pathways
    • Working with Aboriginal and Torres Strait Islander people
    • Multidisciplinary care
    • Psychosocial care
    • Follow-up care
    • Family cancer clinics
    • Cancer Learning
    • Consumer engagement
  • Key initiatives
    • For Aboriginal and Torres Strait Islander people
    • Australian Cancer Plan
    • Australian Brain Cancer Mission
    • Jeannie Ferris Award
    • Lung Cancer Screening
    • National Pancreatic Cancer Roadmap
    • Campaigns & events

Ovarian cancer

ovarian-mm cancer-types/ovarian-cancer/overview
    • Home
    • Types
    • Statistics
    • Risk factors
    • Screening
    • Symptoms
    • Diagnosis
    • Treatment
    • Family history
    • Finding support
    • Clinical trials
    • Health professionals
    • Awareness
    • Home
    • Types
    • Statistics
    • Risk factors
    • Screening
    • Symptoms
    • Diagnosis
    • Treatment
    • Family history
    • Finding support
    • Clinical trials
    • Health professionals
    • Awareness
  1. Home
  2. Statistics
Loading...

Ovarian cancer statistics in Australia

  • Printer-friendly version
  • A|A

The following material has been sourced from the Australian Institute of Health and Welfare

Ovarian cancer statistics for mortality (deaths) incorporate ICD-10 cancer code C56 (Malignant neoplasm of ovary) only. For incidence, survival and prevalence, statistics also include ICD-10 cancer codes C57.0, C57.8 (with histologies 8441, 8460, 8461) for serous carcinomas of the fallopian tube.


Estimated number of new cases of ovarian cancer (incl. serous carcinomas of the fallopian tube) diagnosed in 2022

Female icon PNG 1,815 females


Estimated % of all new cancers in females diagnosed in 2022

2.5%


Estimated number of deaths from ovarian cancer in 2022

Female icon PNG 1,016 females


Estimated % of all female deaths from cancer in 2022

4.6%


Chance of surviving at least 5 years (2014–2018)

49%


People living with ovarian cancer (incl. serous carcinomas of the fallopian tube) at the end of 2017 (diagnosed in the 5-year period 2013 to 2017)

5,035


New cases

In 2018, there were 1,710 new cases of ovarian cancer (incl. serious carcinomas of the fallopian tube) diagnosed in Australia. In 2022, it is estimated that 1,815 new cases of ovarian cancer (incl. serious carcinomas of the fallopian tube) will be diagnosed in Australia. In 2022, it is estimated that a female has a 1 in 84 (or 1.2%) risk of being diagnosed with ovarian cancer (incl. serous carcinomas of the fallopian tube) by the age of 85.

Figure 1. Estimated cancer incidence in Australia among females, 2022

Notes 

  • Data sourced from AIHW Cancer Data in Australia 2022 web report and supplementary data tables
  • More information about incidence rates for ovarian cancer over time, by age, sex, Indigenous status, remoteness, and socioeconomic status (SES) can be found on the NCCI website in the ‘Cancer incidence’ section (https://ncci.canceraustralia.gov.au/diagnosis/cancer-incidence/cancer-incidence)
  • *Ovarian cancer includes serous carcinomas of the fallopian tube. 

In 2018, the age-standardised incidence rate was 11 cases per 100,000 females. In 2022, it is estimated that the age-standardised incidence rate will be 11 cases per 100,000 females. The incidence rate for ovarian cancer (incl. serious carcinomas of the fallopian tube) is expected to increase with age, highest for those aged 85–89 years.

Figure 2. Age-standardised incidence rates for ovarian cancer (incl. serous carcinomas of the fallopian tube), 1982 to 2018

Notes 

  • Data sourced from AIHW Cancer Data in Australia 2022 web report and supplementary data tables 
  • More information about incidence rates for ovarian cancer over time, by age, sex, Indigenous status, remoteness, and socioeconomic status (SES) can be found on the NCCI website in the ‘Cancer incidence’ section (https://ncci.canceraustralia.gov.au/diagnosis/cancer-incidence/cancer-incidence)

The number of new cases of ovarian cancer (incl. serious carcinomas of the fallopian tube) diagnosed increased from 837 females in 1982 to 1,360 in 2018. Over the same period, the age-standardised incidence rate remained similar from 13 cases per 100,000 females in 1982 to 11 cases per 100,000 in 2018.

Deaths 

In 2020, there were 944 deaths from ovarian cancer in Australia. In 2022, it is estimated that there will be 1,016 deaths. In 2022, it is estimated that a female has a 1 in 148 (or 0.68%) risk of dying from ovarian cancer by the age of 85. 

Figure 3. Estimated cancer mortality in Australia among females, 2022

Notes 

  • Data sourced from AIHW Cancer Data in Australia 2022 web report and supplementary data tables
  • More information about mortality rates for ovarian cancer over time, by age, sex, Indigenous status, remoteness, and socioeconomic status (SES) can be found on the NCCI website in the ‘Cancer mortality’ section (https://ncci.canceraustralia.gov.au/outcomes/cancer-mortality/cancer-mortality)

In 2020, the age-standardised mortality rate was 5.6 deaths per 100,000 females. In 2022, it is estimated that the age-standardised mortality rate will be 5.7 deaths per 100,000 females. The mortality rate for ovarian cancer is expected to increase with age.Mortality rates for ovarian cancer

Figure 4. Age-standardised mortality rates for ovarian cancer, 1982 to 2020

Notes 

  • Data sourced from AIHW Cancer Data in Australia 2022 web report and supplementary data tables
  • More information about mortality rates for ovarian cancer over time, by age, sex, Indigenous status, remoteness, and socioeconomic status (SES) can be found on the NCCI website in the ‘Cancer mortality’ section (https://ncci.canceraustralia.gov.au/outcomes/cancer-mortality/cancer-mortality)

The number of deaths from ovarian cancer increased from 587 females in 1982 to 944 in 2020. Over the same period, the age-standardised mortality rate decreased from 8.8 deaths per 100,000 females in 1982 to 5.6 deaths per 100,000 in 2020. 

Survival 

In 2014–2018, individuals diagnosed with ovarian cancer (incl. serious carcinomas of the fallopian tube) had a 49% chance of surviving for five years compared to their counterparts in the general Australian population. Between 1989–1993 and 2014–2018, five-year relative survival for ovarian cancer (incl. serious carcinomas of the fallopian tube) improved from 39% to 49%. 

Figure 5. 5-year relative survival for ovarian cancer and serous carcinomas of the fallopian tube, 1989–1993 to 2014–2018

Notes 

  • Data sourced from AIHW Cancer Data in Australia 2022 web report and supplementary data tables
  • More information about 5-year relative survival rates for ovarian cancer over time, by age, sex, Indigenous status, remoteness, and socioeconomic status (SES) can be found on the NCCI website in the ‘Relative survival rate’ section (https://ncci.canceraustralia.gov.au/outcomes/relative-survival-rate/5-year-relative-survival)

Prevalence 

At the end of 2017, there were 1,397 people living who had been diagnosed with ovarian cancer (incl. serious carcinomas of the fallopian tube) that year, 5,035 people living who had been diagnosed with ovarian cancer (incl. serious carcinomas of the fallopian tube) in the previous 5 years (from 2013 to 2017) and 13,154 people living who had been diagnosed with ovarian cancer (incl. serious carcinomas of the fallopian tube) in the previous 36 years (from 1982 to 2017).

For more information, see Ovarian cancer on the NCCI website 

The National Cancer Control Indicators (NCCI) are a set of indicators across the continuum of cancer care, from Prevention and Screening through to Diagnosis, Treatment, Psychosocial care, Research and Outcomes.  The NCCI website allows users to see visual representations of data on each indicator through interactive charts. 

  • Last Updated
  • Relevant Links
updated: 1 September 2022 - 12:10pm
Cancer Australia, Epithelial ovarian cancer: understanding your diagnosis and treatment
Cancer Australia, Intimacy and sexuality for women with gynaecological cancer – starting a conversation
Cancer Australia Familial Risk Assesment For Breast and Ovarian Cancer
American Cancer Society, Ovarian cancer
National Cancer Institute (US), Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment (PDQ®), patient vers
National Cancer Institute (US), Ovarian germ cell tumors treatment (PDQ®), patient version
National Cancer Institute (US), Ovarian low malignant potential tumors treatment (PDQ®), patient version
National Comprehensive Cancer Network (US), NCCN guidelines for patients: ovarian cancer
Australian Cancer Trials

Related information

What is cancer?
What is cancer?

Cancer is a disease of the cells, which are the body’s basic building blocks.

Treatment and side effects
Treatment and side effects

The treatment that your doctors recommend will depend on the type of cancer you have, how advanced it is, and other personal factors.

Living with cancer
Living with cancer

A diagnosis of cancer marks the beginning of a journey full of emotional, psychological, physical and practical challenges.

Life after cancer
Life after cancer

While looking forward to finishing their cancer treatment and getting on with life, for some people, the end of treatment can also be a confusing or worrying time.

A-Z List of Cancer Types

Information on more than 70 types of cancer

  • Bladder cancer
  • Bowel cancer
  • Brain cancer
  • Breast cancer
  • Breast cancer in men
  • Breast cancer in young women
  • Cervical cancer
  • Children's Cancer
  • Endometrial cancer
  • Fallopian cancer
  • Gestational trophoblastic disease
  • Gynaecological cancers
  • Head and neck cancer
  • Kidney cancer
  • Leukaemia
  • Liver cancer
  • Lung cancer
  • Lymphoma
  • Melanoma of the skin
  • Mesothelioma cancer
  • Myeloma
  • Neuroendocrine tumours
  • Oesophageal cancer
  • Ovarian cancer
  • Pancreatic cancer
  • Prostate cancer
  • Sarcoma
  • Stomach cancer
  • Testicular cancer
  • Thyroid cancer
  • Unknown primary
  • Uterine sarcoma
  • Vaginal cancer
  • Vulval cancer

About Cancer Australia

Cancer Australia was established by the Australian Government in 2006 to benefit all Australians affected by cancer, and their families and carers. Cancer Australia aims to reduce the impact of cancer, address disparities and improve outcomes for people affected by cancer by leading and coordinating national, evidence-based interventions across the continuum of care.

If you would like an interpreter to help you understand any information on this website, please call TIS National on 131 450 and ask them to call Cancer Australia on 02 9357 9400. Our business hours are 9am to 5pm, Monday to Friday.

Freecall 1800 624 973
+61 2 9357 9400

Locked Bag 3, Strawberry Hills
NSW 2012

Navigation

  • Cancer types
  • Impacted by Cancer
  • Awareness
  • Research
  • Resources
  • Clinicians hub
  • Key initiatives

Contact us

* Denotes mandatory fields
 

By submitting this form, you accept the Cancer Australia privacy policy.

  • Contact Us
  • Copyright
  • Disclaimer
  • Privacy policy
  • Sitemap
Copyright © 2023 - Cancer Australia